FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891982042> ?p ?o ?g. }

• W2891982042 abstract "e22012 Background: New treatments are needed to improve outcomes for pediatric gliomas. Immune checkpoint inhibitors are effective therapies in tumors with a high mutation burden that express multiple neo-antigens. However, for pediatric tumors that carry few mutations, there is a need to identify new antigenic targets of anti-tumor immunity. SOX2 is an embryonal stem cell antigen implicated in the biology of glioma initiating cells. Expression of SOX2 by pediatric glial tumors, and the capacity of the immune system in these patients to recognize SOX2, has not been studied. Methods: We examined the expression of SOX2 on paraffin-embedded tissue from pediatric glial tumors (n = 30). The presence of T cell immunity to SOX2 was examined in both blood and tumor-infiltrating T cells using antigen-dependent cytokine and T cell proliferation assays (n = 15). The nature of tumor-infiltrating immune cells in glial tumors (n = 4) was analyzed using single cell mass cytometry. Results: SOX2 is expressed by tumor cells but not surrounding normal tissue in all low grade gliomas (n = 15), high grade gliomas (n = 7), ependymomas (n = 3) and in 60% of oligodendrogliomas (n = 5). T cells against SOX2 can be detected in blood and tumor tissue in 33% of patients. CD4 and CD8 tumor infiltrating T-cells display a higher proportion of PD-1 expression compared to circulating T cells (p < 0.05). Glial CD4 and CD8 T cells are enriched for tissue resident memory phenotype (T RM ; CD45RO + , CD69 + , CCR7 - ) and the expression of PD-1 is primarily on these T RM cells (p < 0.05). A subset of CD4 and CD8 T RM cells also co-express multiple inhibitory checkpoints including PD-L1 and TIGIT. Glial tumors also contain NK cells with reduced expression of lytic granzyme (p < 0.05). Conclusions: Our data demonstrate in vivo immunogenicity of SOX2, which is specifically overexpressed on pediatric glial tumor cells. Our data also suggest that the T RM subset of tumor-infiltrating T cells may be key targets for immune checkpoint blockade, and harnessing tumor immunity will likely require the combined targeting of multiple inhibitory checkpoints. Future efforts to target SOX2 with dendritic cell vaccines combined with immune checkpoint blockade could provide effective tumor immunity and improve outcomes in pediatric brain tumors." @default.
• W2891982042 created "2018-09-27" @default.
• W2891982042 creator A5005427159 @default.
• W2891982042 creator A5007901652 @default.
• W2891982042 creator A5021541475 @default.
• W2891982042 creator A5023990079 @default.
• W2891982042 creator A5054285059 @default.
• W2891982042 creator A5058936141 @default.
• W2891982042 creator A5062737849 @default.
• W2891982042 creator A5073098256 @default.
• W2891982042 date "2017-05-20" @default.
• W2891982042 modified "2023-09-28" @default.
• W2891982042 title "SOX2 as a target for immunotherapy of pediatric gliomas." @default.
• W2891982042 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e22012" @default.
• W2891982042 hasPublicationYear "2017" @default.
• W2891982042 type Work @default.
• W2891982042 sameAs 2891982042 @default.
• W2891982042 citedByCount "1" @default.
• W2891982042 countsByYear W28919820422020 @default.
• W2891982042 crossrefType "journal-article" @default.
• W2891982042 hasAuthorship W2891982042A5005427159 @default.
• W2891982042 hasAuthorship W2891982042A5007901652 @default.
• W2891982042 hasAuthorship W2891982042A5021541475 @default.
• W2891982042 hasAuthorship W2891982042A5023990079 @default.
• W2891982042 hasAuthorship W2891982042A5054285059 @default.
• W2891982042 hasAuthorship W2891982042A5058936141 @default.
• W2891982042 hasAuthorship W2891982042A5062737849 @default.
• W2891982042 hasAuthorship W2891982042A5073098256 @default.
• W2891982042 hasConcept C143998085 @default.
• W2891982042 hasConcept C203014093 @default.
• W2891982042 hasConcept C2777701055 @default.
• W2891982042 hasConcept C502942594 @default.
• W2891982042 hasConcept C71924100 @default.
• W2891982042 hasConcept C8891405 @default.
• W2891982042 hasConceptScore W2891982042C143998085 @default.
• W2891982042 hasConceptScore W2891982042C203014093 @default.
• W2891982042 hasConceptScore W2891982042C2777701055 @default.
• W2891982042 hasConceptScore W2891982042C502942594 @default.
• W2891982042 hasConceptScore W2891982042C71924100 @default.
• W2891982042 hasConceptScore W2891982042C8891405 @default.
• W2891982042 hasLocation W28919820421 @default.
• W2891982042 hasOpenAccess W2891982042 @default.
• W2891982042 hasPrimaryLocation W28919820421 @default.
• W2891982042 hasRelatedWork W1973988089 @default.
• W2891982042 hasRelatedWork W2006960645 @default.
• W2891982042 hasRelatedWork W2007834382 @default.
• W2891982042 hasRelatedWork W2046165324 @default.
• W2891982042 hasRelatedWork W2080789936 @default.
• W2891982042 hasRelatedWork W2095715696 @default.
• W2891982042 hasRelatedWork W2154251503 @default.
• W2891982042 hasRelatedWork W2417787074 @default.
• W2891982042 hasRelatedWork W2499969595 @default.
• W2891982042 hasRelatedWork W2552210919 @default.
• W2891982042 hasRelatedWork W2596407299 @default.
• W2891982042 hasRelatedWork W2742534733 @default.
• W2891982042 hasRelatedWork W2775289566 @default.
• W2891982042 hasRelatedWork W2784096863 @default.
• W2891982042 hasRelatedWork W2949682695 @default.
• W2891982042 hasRelatedWork W2981999157 @default.
• W2891982042 hasRelatedWork W3015150584 @default.
• W2891982042 hasRelatedWork W3048793083 @default.
• W2891982042 hasRelatedWork W3133919490 @default.
• W2891982042 hasRelatedWork W3138663032 @default.
• W2891982042 isParatext "false" @default.
• W2891982042 isRetracted "false" @default.
• W2891982042 magId "2891982042" @default.
• W2891982042 workType "article" @default.